Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer
Description
In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches.
Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Associate Director of Clinical Research and Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. A graduate of the University of Washington School of Medicine, WA, Dr. Moore completed her residency in gynecology at the University Health Center of Pittsburgh in Pittsburgh, PA and completed a fellowship in gynecologic oncology at the University of Oklahoma College of Medicine in Oklahoma City, OK. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care.
For more information, visit: https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html
For patient resources, please visit TestForHRD.com.
This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokeperson's opinions and experience.
United States
